businesses - Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products. Since 2008, however, the drug maker went through a very difficult phase. The acquisition of German generics company betapharm Arzneimittel GmbH (Betapharm) in 2006 backfired, sinking the company into its worst ever quarterly loss in the fiscal 2008-09. Pending lawsuits for alleged patent infringements prevented DRL from launching generic products in its biggest market, the US. Moreover the ban imposed
Words: 1901 - Pages: 8
Claris Lifesciences Claris Lifescienceswas originally founded as Oracle Laboratories Limited on July 19, 1994, as a public limited company. They received the certificate for commencement of business on July 28, 1994. Subsequently, the company name was changed to Core Laboratories Limited as they were acting as the marketing and distribution agent for Core Healthcare Limited at the time. They changed the name of the Company again to Claris Lifesciences Limited on March 31, 1999. Since then, Claris
Words: 835 - Pages: 4
Government-created Monopoly of pharmaceutical companies Not to long ago, the Chinese government amended its patent laws to allow drug companies to reproduce generic, low-cost versions of expensive, patented drugs, a daring move that I am sure will shake up the pharmaceutical industry, as for “Big Pharma” patents ensure a steady stream of exorbitant profits from new drugs for many years. For example, in the U.S., these patents could last 20 years from the time they are first filed, which results
Words: 296 - Pages: 2
carbon which comes from their pharmaceutical industries. Different strategies could be used to reduce carbon and chemical waste from drugs for human environment, like proper consumption ,good way of savages for hospitals waste water like advance waste water treatment technology, private house hold expire drugs, training and education of medical professionals to reduce over prescription, and public education and awareness. These strategies could be help full for save green house environment from drugs
Words: 1468 - Pages: 6
1- Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. (9 points) * PESTEL analysis of the pharmaceutical industry: Political: Since the creation of healthcare insurance, companies have to conform themselves to two kinds of systems: 1) The universal system applied for example in France, with less demand in new technologies. 2) The very selective anglo-saxon system which is looking for high
Words: 1150 - Pages: 5
Generic drugs are copies of brand-name drugs that have exactly the same dosage, intended use, effects, sideeffects, and route of administration, risks, safety, and strength as the original drug. In other words, their pharmacological effects are exactly the same as those of their brand-name counterparts. Many people become concerned because generic drugs are often substantially cheaper than the brand-name versions. They wonder if the quality and effectiveness have been compromised to make
Words: 1583 - Pages: 7
The Upjohn Company: The Upjohn - Pharmacia Merger 3 Business Analysis and Valuation Applications harmacia & Upjohn will be a powerful new competitor in the global pharmaceutical industry. For both Pharmacia and Upjohn, this merger is a bold strategic move to build a highly competitive company as the worldwide pharmaceutical industry continues to consolidate. The new company will be positioned to attain its goals of revenue growth above the industry average and operating margins exceeding 25%
Words: 13956 - Pages: 56
Course Project: Merck Pharmaceutical Sydney Momoh Tanika Thomas PM587 Prof. Susan Orr June 9th, 2012 Table of Contents 1.0 Introduction of Merck Company………………………………………………………..…..3 2.0 Organization Strategic Plan………………………………………..…………………………3 • Sustainability of loyal customers and employees • Change to meet customers demand • Growth will strengthen the company through acquisitions ……………………….4 3.0 Strategic Capacity Plan………………………………………………………………………4 4.0 Portfolio Management Process……………………………………………………………
Words: 3445 - Pages: 14
Harvard Business School 9-197-034 Rev. February 28, 1997 The Upjohn Company: The Upjohn - Pharmacia Merger Pharmacia & Upjohn will be a powerful new competitor in the global pharmaceutical industry. For both Pharmacia and Upjohn, this merger is a bold strategic move to build a highly competitive company as the worldwide pharmaceutical industry continues to consolidate. The new company will be positioned to attain its goals of revenue growth above the industry average and operating margins
Words: 14768 - Pages: 60
industries, with the Palestinian companies owning 55% and 30% market share of the private and public sectors respectively, and high potential of growth even more, in a market estimated at around USD 100 million. All these companies mostly reproduce generics that are seen as commodities rather than differentiated, and highly depend on preferred agreements with pharmacies, doctors, hospitals and medical centers to serve both as their marketing and distribution channels. All operating firms in the industry
Words: 1927 - Pages: 8
